JP2024522350A - 転写状態およびタンパク質組織像の共マッピング - Google Patents

転写状態およびタンパク質組織像の共マッピング Download PDF

Info

Publication number
JP2024522350A
JP2024522350A JP2023573328A JP2023573328A JP2024522350A JP 2024522350 A JP2024522350 A JP 2024522350A JP 2023573328 A JP2023573328 A JP 2023573328A JP 2023573328 A JP2023573328 A JP 2023573328A JP 2024522350 A JP2024522350 A JP 2024522350A
Authority
JP
Japan
Prior art keywords
cells
oligonucleotide probe
disease
cell
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023573328A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522350A5 (enExample
Inventor
ワン，シャオ
ゼン，フー
レン，ジンイー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Broad Institute Inc
Original Assignee
Broad Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broad Institute Inc filed Critical Broad Institute Inc
Publication of JP2024522350A publication Critical patent/JP2024522350A/ja
Publication of JP2024522350A5 publication Critical patent/JP2024522350A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/161—Modifications characterised by incorporating target specific and non-target specific sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/125—Rolling circle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/162—Helper probe
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/179—Nucleic acid detection characterized by the use of physical, structural and functional properties the label being a nucleic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023573328A 2021-05-28 2022-05-27 転写状態およびタンパク質組織像の共マッピング Pending JP2024522350A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163194536P 2021-05-28 2021-05-28
US63/194,536 2021-05-28
PCT/US2022/031275 WO2022251586A1 (en) 2021-05-28 2022-05-27 Co-mapping transcriptional states and protein histology

Publications (2)

Publication Number Publication Date
JP2024522350A true JP2024522350A (ja) 2024-06-18
JP2024522350A5 JP2024522350A5 (enExample) 2025-06-03

Family

ID=82321599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023573328A Pending JP2024522350A (ja) 2021-05-28 2022-05-27 転写状態およびタンパク質組織像の共マッピング

Country Status (9)

Country Link
US (1) US20240376530A1 (enExample)
EP (2) EP4347878B1 (enExample)
JP (1) JP2024522350A (enExample)
KR (1) KR20240014486A (enExample)
CN (1) CN117813395A (enExample)
AU (1) AU2022281407A1 (enExample)
CA (1) CA3219339A1 (enExample)
IL (1) IL308570A (enExample)
WO (1) WO2022251586A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12359253B2 (en) 2018-04-09 2025-07-15 The Board Of Trustees Of The Leland Stanford Junior University Method of in situ gene sequencing
US12497651B2 (en) 2020-11-23 2025-12-16 Pleno, Inc. Encoded dual-probe endonuclease assays
DE102022131444A1 (de) * 2022-11-28 2024-05-29 Carl Zeiss Microscopy Gmbh Verfahren zum Identifizieren von Analyten in einer Bildfolge
CN116189880A (zh) * 2023-01-21 2023-05-30 中国医学科学院北京协和医院 一种肺腺癌脑转移的预测指标及预测方法和应用
WO2025136916A1 (en) 2023-12-18 2025-06-26 The Board Institute, Inc. Thick tissue transcriptomics and translatomics
WO2025189030A1 (en) 2024-03-07 2025-09-12 Stellaromics, Inc. Methods and systems for volumetric imaging
CN119068988B (zh) * 2024-08-13 2025-04-15 北京国浩宇医疗科技有限公司 一种针对单细胞表达谱的智能化异常检测系统

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201107863D0 (en) * 2011-05-11 2011-06-22 Olink Ab Method and product
WO2014163886A1 (en) * 2013-03-12 2014-10-09 President And Fellows Of Harvard College Method of generating a three-dimensional nucleic acid containing matrix
WO2017079406A1 (en) * 2015-11-03 2017-05-11 President And Fellows Of Harvard College Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix
CA3007292A1 (en) * 2015-12-02 2017-06-08 Clearlight Diagnostics Llc Methods for preparing and analyzing tumor tissue samples for detection and monitoring of cancers
WO2018035055A1 (en) * 2016-08-19 2018-02-22 Arizona Board Of Regents On Behalf Of Arizona State University High throughput oil-emulsion synthesis of bowtie barcodes for paired mrna capture and sequencing from individual cells
US20180208975A1 (en) * 2017-01-20 2018-07-26 Merck Sharp & Dohme Corp. Assay for simultaneous genomic and proteomic analysis
US12359253B2 (en) 2018-04-09 2025-07-15 The Board Of Trustees Of The Leland Stanford Junior University Method of in situ gene sequencing
US20230109070A1 (en) * 2019-10-18 2023-04-06 The Board of Trustees og the Leland Standford Junior University Clinical- and industrial-scale intact-tissue sequencing
EP4484571A3 (en) * 2020-02-21 2025-03-19 10X Genomics, Inc. Methods and compositions for integrated in situ spatial assay
US12060603B2 (en) * 2021-01-19 2024-08-13 10X Genomics, Inc. Methods for internally controlled in situ assays using padlock probes
CN114854838A (zh) * 2021-02-04 2022-08-05 美天施生物科技有限两合公司 结合靶向RNA或cDNA体外测序与原位测序的方法

Also Published As

Publication number Publication date
CN117813395A (zh) 2024-04-02
EP4644569A2 (en) 2025-11-05
CA3219339A1 (en) 2022-12-01
IL308570A (en) 2024-01-01
WO2022251586A1 (en) 2022-12-01
EP4644569A3 (en) 2026-01-07
US20240376530A1 (en) 2024-11-14
EP4347878A1 (en) 2024-04-10
KR20240014486A (ko) 2024-02-01
AU2022281407A1 (en) 2023-11-30
EP4347878B1 (en) 2025-07-16

Similar Documents

Publication Publication Date Title
EP4347878B1 (en) Co-mapping transcriptional states and protein histology
Phan et al. A myelin-related transcriptomic profile is shared by Pitt–Hopkins syndrome models and human autism spectrum disorder
Utz et al. Early fate defines microglia and non-parenchymal brain macrophage development
Duy et al. Impaired neurogenesis alters brain biomechanics in a neuroprogenitor-based genetic subtype of congenital hydrocephalus
Barrenschee et al. Distinct pattern of enteric phospho-alpha-synuclein aggregates and gene expression profiles in patients with Parkinson’s disease
Adua et al. Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer
Tranchevent et al. Systems level analysis of sex-dependent gene expression changes in Parkinson’s disease
US20210164051A1 (en) Methods of detection and analysis of nucleic acid in neural-derived exosomes
JP2024529290A (ja) Ｒｎａの翻訳状態の単一細胞プロファイリング
US20190085394A1 (en) Refining diagnosis and treatment of complex multi-symptom neurological disorders
Piras et al. Association of AEBP1 and NRN1 RNA expression with Alzheimer’s disease and neurofibrillary tangle density in middle temporal gyrus
Zhang et al. Inhibiting ceramide synthase 5 expression in microglia decreases neuroinflammation after spinal cord injury
Shao et al. Single-cell sequencing reveals the expression of immune-related genes in macrophages of diabetic kidney disease
Epstein et al. Subventricular zone stem cell niche injury is associated with intestinal perforation in preterm infants and predicts future motor impairment
Gaunt et al. Cytokine enrichment in deep cerebellar nuclei is contributed by multiple glial populations and linked to reduced amyloid plaque pathology
Crociara et al. Cellular and molecular characterization of multipolar Map5-expressing cells: a subset of newly generated, stage-specific parenchymal cells in the mammalian central nervous system
Demenego et al. Neurodevelopmental origins of structural and psychomotor defects in CXCR4-linked primary immunodeficiency
EP4480478A1 (en) Screening method and therapeutic agent for mental disorder
CN108588214A (zh) 联合Aβ和D-gal构建的AD模型鼠海马区基因表达差异谱及其测定方法和应用
Lu et al. Single-cell transcriptomics reveals ependymal subtypes related to cytoskeleton dynamics as the core driver of syringomyelia pathological development
Fenu et al. Relationship between CSF tau biomarkers and structural brain MRI measures in frontotemporal lobar degeneration
Ehrenberg et al. Mislocalization and clearance of neuronal Rhes as a novel hallmark of tauopathies
Gallotti Validating advanced MRI features as surrogate biomarkers of the molecular subgroups of glioblastoma by exploiting patient-specific cancer stem cell (CSC)-based animal models.
Scholl et al. Neurite Outgrowth Inhibitor (NogoA) Is Upregulated in White Matter Lesions of Complex Cortical Malformations
Martín Integration of multiplex imaging, machine learning and single cell transcriptomic analyses in the characterization of focal cortical dysplasia and other malformations of cortical development

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250526